September 2023 - BioMedWire (BMW)

FridaySep 29, 2023 2:50 pm

CDC Avails $262M to New Network Aimed at Responding to Future Disease Outbreaks

The Centers for Disease Control (CDC) will provide $262 million to fund the development of a new disease outbreak response network. Per the announcement, recipients will receive grants from the pool of more than $250 million to establish America’s first-ever response network in anticipation of future disease outbreaks. The grants will fund the development and implementation of new tools meant to detect and mitigate public health emergencies such as pandemics and disease outbreaks in the future. According to a statement from the CDC, it will distribute funds for the development of the Outbreak Analytics and Disease Modeling Network (OADMN) to…

FridaySep 29, 2023 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program With NDA approval, we anticipate the potential to…

FridaySep 29, 2023 9:00 am

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

by Elaine Mendonça On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8. The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites. To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function,…

ThursdaySep 28, 2023 2:21 pm

Eliminating Barriers Surrounding Solid Tumors Allows T Cells to Kill Cancerous Cells

A recent University of Pennsylvania study has found that getting rid of the barriers surrounding solid tumors allows T cells to kill cancer cells more effectively. The research indicates that it is possible to make immunotherapies more effective at treating solid tumors such as lung cancer and pancreatic cancer. Immunotherapy is a relatively new type of cancer treatment that involves “training” the immune system to make it more effective at identifying and killing cancerous cells in the body. However, while this treatment has proven to be relatively effective at treating blood cancers, immunotherapies rarely have an impact on solid cancers.…

ThursdaySep 28, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11% RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products…

ThursdaySep 28, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…

WednesdaySep 27, 2023 11:43 am

How to Maximize ROI from an eCommerce Advertising Budget

With Americans spending hundreds of billions of dollars on online purchases every year, e-commerce is one of the largest platforms for trade in the country. It allows companies to significantly broaden their potential customer base and provides varied and affordable means of marketing and advertising. With an estimated 2.5 million online retailers in the United States alone and 9.1 million on the entire globe, a proper marketing and advertising strategy will be key to attracting a sufficient customer base and building a respectable brand. Maximizing ROI on advertising will allow you to bring in as much value as possible from…

WednesdaySep 27, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who…

TuesdaySep 26, 2023 2:33 pm

Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery

Researchers from Boston Children’s Hospital say they have created a prototype surgical tool that can allow surgeons to remove pediatric brain tumors safely and in a less invasive manner. The surgical robot uses hollow, nitinol robot arms to give surgeons the ability to switch tools during tumor resections and could also have applications for neurosurgery in adults and other surgical procedures. Study coauthor and Boston Children’s Hospital chief of pediatric cardiac bioengineering Pierre DuPont said the idea for the project goes back to 2016 when he had conversations with Dr. Jim Drake, the chief of neurosurgery at Toronto-based SickKids. DuPont…

TuesdaySep 26, 2023 9:00 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027 RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: September 2023

CDC Avails $262M to New Network Aimed at Responding to Future Disease Outbreaks

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

Eliminating Barriers Surrounding Solid Tumors Allows T Cells to Kill Cancerous Cells

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

How to Maximize ROI from an eCommerce Advertising Budget

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search